Cassava Sciences to Provide Corporate Update on Alzheimer's Drug Simufilam
Key Insights
Cassava Sciences (search) will host a conference call and webcast on November 25th to provide a corporate update.
The update will likely cover the ongoing Phase 3 clinical trials of Simufilam, an investigational drug for Alzheimer's disease.
Simufilam is an oral small molecule that targets filamin A (search) protein, with Cassava Sciences (search) holding worldwide rights.
Cassava Sciences (search), Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company, will hold a conference call and webcast on Monday, November 25th, at 8:00 a.m. Eastern Time to provide a corporate update. The focus is expected to be on Simufilam, Cassava's investigational drug for Alzheimer's disease.
Simufilam is currently being evaluated in two Phase 3 clinical trials. It is an oral small molecule designed to target the filamin A (search) protein. Cassava Sciences (search) retains exclusive, worldwide rights to Simufilam and related technologies.
Simufilam's Mechanism of Action
Simufilam is designed to restore the normal shape and function of altered filamin A (search) protein in the Alzheimer's brain. The company believes this approach can potentially improve multiple aspects of the disease.
Alzheimer's Disease: An Unmet Need
Alzheimer's disease is a progressive neurodegenerative disorder affecting millions worldwide. Current treatments offer limited symptomatic relief, highlighting the urgent need for disease-modifying therapies. According to the Alzheimer's Association, an estimated 6.7 million Americans aged 65 and older are living with Alzheimer's in 2023.
Webcast Details
A replay of the audio webcast will be available on the Company Presentations page of the Cassava Sciences (search) website for 90 days following the webcast.